series-a
Stage
2
Investors
About
Rna Diagnostics is a clinical-stage molecular diagnostics company developing a predictive biomarker platform, Veridapt DX™, that measures tumor response to cancer drugs for early evaluation of therapy efficacy in solid tumors, initially focusing on primary breast cancer.
Explore Rna Diagnostics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.